Practices to enable more-thorough, earlier analyses of failed developments should be adapted to treatments for other challenging diseases, and should be part of regulators’ responsibilities. This will ensure that clinical research evaluates treatments faster and with more certainty.
Access to evidence from disappointing drug-development programmes advances the whole scientific process, explain Enrica Alteri and Lorenzo Guizzaro.
Read more
Comments are closed.